“Prospective Real-Life Multicenter Study of Tildrakizumab 200 mg for Moderate-to-Severe Psoriasis: Who Is the Ideal Patient?”, Dermatol Pract Concept, vol. 14, no. 4, p. e2024284, Oct. 2024, doi: 10.5826/dpc.1404a284.